查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542950

全球造影剂市场 - 2024-2031

Global Contrast Agents Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

全球造影剂市场在 2023 年达到 62 亿美元，预计到 2031 年将达到 98.6 亿美元，2024-2031 年预测期间复合年增长率为 6.1%。

造影剂（或造影剂）可增加医学影像中体内结构或液体的对比。造影剂吸收或改变外部电磁或超音波，这与发射辐射的放射性药物不同。造影剂是一组化学试剂，旨在透过提高成像模式的对比度分辨率来帮助表征病理学。已经针对每种结构成像方式和每种可能的给药途径开发了特定的造影剂。

硫酸钡造影剂已经使用了几十年，并且是公认的用于检查胃肠道的口服製剂。它们的使用通常仅限于放射线照相和萤光镜检查。碘造影剂是用于放射线照相、透视、血管造影和 CT 成像的主要造影剂。它们是一组用途广泛的药物，用于静脉注射、口服和其他给药途径，例如尿道和关节内给药。

市场动态：

司机

放射学和诊断中心数量的增加以及放射学和诊断领域的进步

全球造影剂市场的需求是由多种因素所驱动的。放射学和诊断中心数量的增加是造影剂市场的主要驱动因素之一。人们对各种诊断和放射学程序的认识不断提高也导致了市场的成长。

根据医疗保健半径，印度诊断影像市场预计未来五年复合年增长率（CAGR）为12-15%。这个数字高于全球 5% 的复合年增长率。慢性病盛行率的上升、影像技术的采用增加以及老年人口的增加预计将推动这一成长。

慢性病、心血管疾病、基因突变和胃肠道疾病发病率的增加预计都会对该行业产生积极影响。医疗保健领域支出的增加和消费者意识的提高也将推动成像和放射学行业的发展。

限制

全球造影剂市场的主要限制之一是与造影剂使用相关的副作用和过敏反应。在诊断过程中，少数人会观察到副作用，这会对身体造成负面影响。根据 NIH 发表的一篇文章，非离子造影剂立即反应的发生率范围为 0.01-0.04%（重度）到 3%（轻度）。非离子製剂的风险较小。

另一个限制是由于成像程序的进步而导致的高成本。高昂的成本限制了造影剂在某些人群中的使用。

细分市场分析

全球造影剂市场根据类型、应用、模式、最终用户和地区进行细分。

分段CT扫描占全球造影剂市占率约48.7%

CT扫描过程中广泛使用显影剂。 Computed tomography scan (CT or CAT scan) is a non-invasive diagnostic imaging procedure that uses a combination of special X-ray equipment and sophisticated computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the身体.然后可以在电脑显示器上检查或列印所研究区域的这些横断面影像。

CT扫描中使用的造影剂的主要成分是碘。 CT造影剂有离子型和非离子型两种。目前，CT扫描中应用最广泛的是非离子造影剂。根据杰斐逊放射学的说法，使用造影剂的 CT 扫描广泛用于可视化内部结构，如骨骼、血管和器官。它们在检测肿瘤、血管疾病和内出血方面特别有用。

例如，2022 年7 月，费森尤斯·卡比(Fresenius Kabi) 宣布将在美国推出一系列仿製药造影剂产品组合，首先推出碘克沙醇注射液(USP)，该产品被美国食品和药物管理局(FDA) 列为全国紧缺。碘克沙醇注射 (USP) 是美国 FDA 批准的第一种通用等渗二聚碘造影剂，用于基于 X 光的诊断成像，例如电脑断层扫描 (CT) 扫描。

市场地理分析

北美约占全球造影剂市场份额的49.2%

预计北美地区将在预测期内占据最大的市场份额。该地区放射学和诊断中心数量的增加以及人们意识的提高有助于推动市场发展。

由于北美地区存在主要参与者，它在诊断和放射学程序方面取得了进展。长期疾病和复杂合併症发病率上升以及私人和当局费用增加等因素预计将推动北美汽油市场的成长

例如，2024 年 1 月，凯斯西储大学的科学家开始研究开发以人工智慧为基础的化学影像造影剂替代品。 CWRU 最近从美国国家科学基金会获得了为期四年、价值 112.5 万美元的资助，以帮助推动其工作。他们正在尽最大努力在 CT、MR 和 X 光检查期间创建一种新方法，在不注射钆等物质的情况下增强影像。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 增加放射学和诊断中心的数量
      • 诊断领域的进步
      • 全球人口中慢性病数量的增加

第 5 章：限制

  • 造影剂成本高
  • 与使用显影剂相关的副作用

第 6 章：机会

第 7 章：影响分析

第 8 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 未满足的需求
  • PESTEL分析
  • 专利分析
  • SWOT分析

第 9 章：按类型

  • 钡对比剂
  • 碘造影剂
  • 钆基造影剂
  • 微泡造影剂
  • 其他的

第 10 章：按申请

  • 肿瘤学
  • 心臟病学
  • 神经病学
  • 其他的

第 11 章：按形态

  • X射线/CT
  • 核磁共振成像
  • 超音波
  • 其他的

第 12 章：最终用户

  • 医院
  • 专科诊所
  • 诊断中心
  • 其他的

第 13 章：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第14章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 15 章：公司简介

  • Bayer AG
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • GE Health Care
  • Bracco diagnostics Inc.,
  • Lantheus Medical Imaging
  • Nano Therapeutics Pvt Ltd.
  • Unijules Life Sciences Ltd.,
  • Guerbet SA
  • Trivitron Healthcare
  • Spago Nanomedical AB
  • Taejoon Pharma (*LIST NOT EXHAUSTIVE)

第 16 章：附录

简介目录
Product Code: MD99

Report Overview

The Global Contrast Agents Market reached US$ 6.2 billion in 2023 and is expected to reach US$ 9.86 billion by 2031, growing at a CAGR of 6.1% during the forecast period 2024-2031.

A contrast agent (or contrast medium) increases the contrast of structures or fluids within the body in medical imaging. Contrast agents absorb or alter external electromagnetism or ultrasound, which differs from radiopharmaceuticals, which emit radiation. Contrast agents are a group of chemical agents developed to aid in the characterization of pathology by improving the contrast resolution of an imaging modality. Specific contrast agents have been developed for every structural imaging modality and every conceivable route of administration.

Barium sulfate contrast media have been used for many decades, and are well-established as oral agents for the examination of the GI tract. Their use is generally restricted to radiographic and fluoroscopic examinations. Iodinated contrast media are the mainstay contrast agents for use in radiographic, fluoroscopic, angiographic, and CT imaging. They are a versatile group of agents used for intravenous, oral, and other routes of administration, such as urethral and intra-articular.

Market Dynamics: Drivers

The rise and increase in the number of radiology and diagnostic centers and advancements in the field of radiology and diagnostics

The demand for the global contrast agents market is driven by multiple factors. The rise and increase in the number of radiology and diagnostic centers is one of the major driving factors in the contrast agents market. The increased awareness among people about various diagnostic and radiology procedures also leads to an increase in the market.

According to the healthcare radius, the Indian diagnostic imaging market is expected to register a compounded annual growth rate (CAGR) of 12-15 percent over the next five years. This number is greater than the global CAGR rate which is pegged at five percent. The rise in prevalence of chronic diseases, increased adoption of technologies in imaging, and a growing elderly/geriatric population are expected to boost the growth.

The increasing incidences of chronic diseases, cardiovascular disorders, genetic mutations, and GI disorders are all expected to impact the industry positively. Increased expenditure on the healthcare sector and greater consumer awareness will also give an impetus to the imaging and radiology industry.

Restraints

One of the major restraints in the global contrast agents market is the side effects and allergic reactions that are associated with the usage of contrast agents. In a few people during the diagnostic procedures, side effects are observed which causes a negative impact on the body. According to an article published by NIH, the incidence of immediate reactions to non-ionic contrast media ranges from, 0.01-0.04%(severe) to 3%(mild). Non-ionic agents are associated with less risk.

Another restraint is the high cost due to advancements in imaging procedures. The high cost limits the usage of contrast agents to certain segments of people.

Market Segment Analysis

The global contrast agents market is segmented based on type, application, modality, end-user, and region.

The segment CT scan accounted for approximately 48.7% of the global contrast agents market share

The contrast agents are widely used in the procedure of CT scans. Computed tomography scan (CT or CAT scan) is a non-invasive diagnostic imaging procedure that uses a combination of special X-ray equipment and sophisticated computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body. These cross-sectional images of the area being studied can then be examined on a computer monitor or printed.

The main component of the contrast material used in the CT scan is iodine. The CT contrast agents are of two types: ionic and non-ionic. At present, in CT scans the non-ionic contrast agents are most widely used. According to Jefferson radiology, CT scans with contrast agents are widely used to visualize internal structures such as bones, blood vessels, and organs. They are particularly useful in detecting tumors, vascular diseases, and internal bleeding.

For instance, in July 2022, Fresenius Kabi announced that it would introduce a portfolio of generic contrast media agents in the United States, starting immediately with the launch of Iodixanol Injection, USP, a product the U.S. Food and Drug Administration (FDA) lists as being in shortage nationwide. Iodixanol Injection, USP is the first U.S. FDA-approved generic iso-osmolar, dimeric iodinated contrast media agent, which is used during diagnostic x-ray-based imaging such as computed tomography (CT) scans.

Market Geographical Analysis

North America accounted for approximately 49.2% of the global contrast agents market share

North America region is expected to hold the largest market share over the forecast period. The increase in the number of radiology and diagnostic centers, and growing awareness among people, in this region, help to propel the market.

Due to the presence of major players in the region of North America, it has advancements in diagnostic and radiology procedures. Factors including the rising incidence of long-term sicknesses and complicated comorbidities and increasing private and authority fees are expected to gasoline market increase in the North U.S.

For instance, in January 2024, Scientists with Case Western Reserve University started researching and working on the development of an artificial intelligence-based alternative to chemical imaging contrast agents. CWRU recently scored a four-year, $1.125 million grant from the National Science Foundation to help fuel its work. They are working their best to create a new approach during CT, MR, and X-ray exams, enhancing images without injecting substances such as gadolinium.

Market Segmentation

By Type

  • Barium-based contrast media
  • Iodinated contrast media
  • Gadolinium-based contrast medium
  • Microbubble-based contrast media

By Application

  • Oncology
  • Cardiology
  • Neurology
  • Others

By Modality

  • X-Ray / CT
  • MRI
  • Ultrasound
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Others

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
  • Middle East and Africa

Market Competitive Landscape

The major global players in the global contrast agents market include Bayer AG, GE Health care, Bracco Diagnostics Inc., Lantheus Medical Imaging, Inc., Nano Therapeutics Pvt Ltd., Unijules Life Sciences Ltd., Guerbet SA, Trivitron Healthcare, Spago Nanomedical AB, Taejoon Pharma among others.

Key Developments

  • In September 2022, Bracco Diagnostics Inc., the United States (U.S.) subsidiary of Bracco Imaging S.p.A., an innovative world leader in diagnostic imaging, announced that the U.S. Food and Drug Administration (FDA) has approved Gadopiclenol Injection, a new, highly stable macrocyclic gadolinium-based contrast agent (GBCA), which shows the highest relaxivity compared to all the other GBCAs available today in the United States.
  • In February 2023, Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced the commercial launch and dosing of the first patient with Elucirem(TM) (gadopiclenol) injection following FDA approval in 2022. This next-generation GBCA from Guerbet, a highly stable macrocyclic gadolinium-based contrast agent (GBCA), has the highest relaxivity in its class for magnetic resonance imaging (MRI) and is indicated for use in adults and children aged 2 years and older.

Why Purchase the Report?

  • To visualize the global contrast agents market segmentation based on type, application, modality, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global contrast agents market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in Excel consisting of key products of all the major players.

The global contrast agents market report would provide approximately 78 tables, figures, and 181 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Modality
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing the number of radiology and diagnostic centers
      • 4.1.1.2. Advancements in the field of diagnostics
      • 4.1.1.3. Increase in the number of chronic diseases in the global population

5. Restraints

  • 5.1. High cost of the contrast agents
  • 5.2. Side effects associated with usage of contrast agents

6. Opportunity

7. Impact Analysis

8. Industry Analysis

  • 8.1. Porter's Five Force Analysis
  • 8.2. Supply Chain Analysis
  • 8.3. Pricing Analysis
  • 8.4. Regulatory Analysis
  • 8.5. Unmet Needs
  • 8.6. PESTEL Analysis
  • 8.7. Patent Analysis
  • 8.8. SWOT Analysis

9. By Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.1.2. Market Attractiveness Index, By Type
  • 9.2. Barium based contrast media*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Iodinated contrast media
  • 9.4. Gadolinium-based contrast media
  • 9.5. Microbubble-based contrast media
  • 9.6. Others

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Oncology*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Cardiology
  • 10.4. Neurology
  • 10.5. Others

11. By Modality

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.1.2. Market Attractiveness Index, By Modality
  • 11.2. X-Ray / CT*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. MRI
  • 11.4. Ultrasound
  • 11.5. Others

12. By End-User

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.1.2. Market Attractiveness Index, By End-User
  • 12.2. Hospitals*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Specialty Clinics
  • 12.4. Diagnostic Centers
  • 12.5. Others

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.7.1. The U.S.
      • 13.2.7.2. Canada
      • 13.2.7.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.7.1. Germany
      • 13.3.7.2. UK
      • 13.3.7.3. France
      • 13.3.7.4. Italy
      • 13.3.7.5. Spain
      • 13.3.7.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.7.1. Brazil
      • 13.4.7.2. Argentina
      • 13.4.7.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.7.1. China
      • 13.5.7.2. India
      • 13.5.7.3. Japan
      • 13.5.7.4. South Korea
      • 13.5.7.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Positioning/Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Bayer AG*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. GE Health Care
  • 15.3. Bracco diagnostics Inc.,
  • 15.4. Lantheus Medical Imaging
  • 15.5. Nano Therapeutics Pvt Ltd.
  • 15.6. Unijules Life Sciences Ltd.,
  • 15.7. Guerbet SA
  • 15.8. Trivitron Healthcare
  • 15.9. Spago Nanomedical AB
  • 15.10. Taejoon Pharma (*LIST NOT EXHAUSTIVE)

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us